(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.83%) $83.15
(-1.16%) $1.619
(-0.43%) $2 337.00
(0.97%) $27.52
(0.66%) $928.20
(-0.16%) $0.933
(-0.14%) $11.01
(-0.22%) $0.799
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.20%
Live Chart Being Loaded With Signals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults...
Stats | |
---|---|
Šios dienos apimtis | 41 555.00 |
Vidutinė apimtis | 54 452.00 |
Rinkos kapitalizacija | 131.23M |
EPS | $0 ( 2024-03-07 ) |
Kita pelno data | ( $-0.220 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.790 |
ATR14 | $0.0100 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Tasse Daniel | Buy | 17 094 | Ordinary Shares |
2024-02-06 | Ndu Adora | Buy | 1 825 | Ordinary Shares |
2023-11-22 | Mohideen Pharis | Sell | 2 245 | Ordinary Shares |
2023-11-20 | Boucinha Virginie | Buy | 113 000 | Employee Stock Option (right to buy) |
2023-11-20 | Boucinha Virginie | Buy | 19 000 | Ordinary Shares |
INSIDER POWER |
---|
99.85 |
Last 57 transactions |
Buy: 29 162 445 | Sell: 1 080 406 |
DBV Technologies S.A. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PLPC | 0.902 |
GPOR | 0.891 |
MCAA | 0.89 |
ENTF | 0.887 |
MLAI | 0.886 |
PPYA | 0.884 |
AHRN | 0.883 |
FRSG | 0.882 |
ACQR | 0.88 |
FTAA | 0.88 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
INCY | -0.916 |
SRTS | -0.904 |
FARO | -0.897 |
BXRX | -0.896 |
NWL | -0.895 |
CDXS | -0.892 |
NURO | -0.888 |
AYTU | -0.888 |
RCKY | -0.886 |
SBAC | -0.88 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
DBV Technologies S.A. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $15.73M |
Bruto pelnas: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2023 |
Pajamos: | $15.73M |
Bruto pelnas: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2022 |
Pajamos: | $4.80M |
Bruto pelnas: | $-16.53M (-344.46 %) |
EPS: | $-0.620 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.890 |
Financial Reports:
No articles found.
DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.